

# Alpha-1-Proteinase Inhibitors: Aralast® NP; Glassia®; Prolastin®-C; Zemaira® (Intravenous)

Document Number: IC-0052

Last Review Date: 04/01/2026

Date of Origin: 01/01/2012

Dates Reviewed: 12/2011, 02/2013, 08/2013, 06/2014, 06/2015, 01/2016, 10/2016, 03/2017, 09/2017, 12/2017, 03/2018, 06/2018, 04/2019, 04/2020, 04/2021, 04/2022, 04/2023, 04/2024, 04/2025, 04/2026

## I. Length of Authorization <sup>13</sup>

- Initial: Prior authorization validity will be provided initially for 12 months (365 days), unless otherwise specified.
  - Acute Graft Versus Host Disease (aGVHD): Prior authorization validity will be provided for a maximum of 8 doses (4 weeks).
- Renewal: Prior authorization validity may be renewed every 12 months (365 days) thereafter, unless otherwise specified.
  - Acute Graft Versus Host Disease (aGVHD): Prior authorization validity may NOT be renewed.

## II. Dosing Limits

**Max Units (per dose and over time) [HCPCS Unit]:**

Emphysema due to alpha-1-antitrypsin (AAT) deficiency

- 2800 billable units every 28 days

aGVHD

- 700 billable units for a total of 8 doses in 28 days (5600 billable units per 28 days)

## III. Initial Approval Criteria <sup>1-5</sup>

Prior authorization validity is provided in the following conditions:

- Patient must have a contraindication, intolerance, or failure to **Glassia® AND Zemaria®** prior to the consideration of another alpha-1 proteinase inhibitor product; **AND**

- Member is at least 18 years of age; **AND**

**Universal Criteria <sup>1-5</sup>**

- Member does NOT have any FDA labeled contraindications to the requested agent; **AND**

**Emphysema due to alpha-1-antitrypsin (AAT) deficiency † (Φ – orphan designation applies only to Prolastin-C) <sup>1-6,7,8,10,14-17</sup>**

- Member has an FEV<sub>1</sub> in the range of 30-65% of predicted; **AND**

- Member has alpha-1-antitrypsin (AAT) deficiency with PiZZ, PiZ (null), or Pi (null, null) phenotypes; **AND**
- Member has clinical evidence of panacinar/panlobular emphysema or centrilobular emphysema; **AND**
- Member has low serum concentration of AAT  $\leq 57$  mg/dL (measured by nephelometry) or  $\leq 11$   $\mu$ M/L (measured by Enzyme-Linked Immunosorbent Assay [ELISA]); **AND**
- Member is not a tobacco smoker; **AND**
- Member is receiving optimal medical therapy (e.g., pharmacologic therapy [e.g., bronchodilators, inhaled corticosteroids, etc.], comprehensive case management, pulmonary rehabilitation, vaccinations, smoking cessation, self-management skills, supplemental oxygen, etc.)

#### Acute Graft Versus Host Disease (aGVHD) ‡<sup>11-13</sup>

- Member has received a hematopoietic stem cell transplant; **AND**
- Used for steroid-refractory acute GVHD; **AND**
- Used in combination with systemic corticosteroids as additional therapy following no response to first-line therapy options

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s);  $\Phi$  Orphan Drug

## IV. Renewal Criteria<sup>1-5</sup>

Prior authorization validity may be renewed based upon the following criteria:

- Member continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Duration of authorization has not been exceeded (*refer to section I*); **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe hypersensitivity reactions, etc.; **AND**

#### Emphysema due to alpha-1-antitrypsin (AAT) deficiency<sup>1-7,17</sup>

- Disease response with treatment as defined by elevation of AAT levels above baseline, substantial reduction in rate of deterioration of lung function as measured by percent predicted FEV<sub>1</sub>, or improvement in CT scan lung density

## V. Dosage/Administration<sup>1-5,13</sup>

Indication	Dose
Emphysema due to AAT deficiency	Administer 60 mg/kg intravenously once weekly
Acute GVHD	Administer 60 mg/kg intravenously on days 1, 4, 8, 12, 16, 20, 24, and 28 for up to 4 consecutive weeks (maximum of 8 doses)

## VI. Billing Code/Availability Information

HCPCS Code(s) & NDC(s):

Drug	Manufacturer	HCPCS code	1 Billable Unit	SDV Size	NDC
Aralast NP (powder)	Takeda Pharmaceuticals USA Inc.	J0256	10 mg	1 g/50 mL	00944-2815-xx
				0.5 g/25 mL	00944-2814-xx
Glassia (solution)	Takeda Pharmaceuticals USA Inc.	J0257	10 mg	1 g/50 mL	00944-2884-xx
Prolastin-C Liquid (solution)	Grifols Therapeutics LLC	J0256	10 mg	500 mg/10 mL	13533-0705-xx
				1 g/20 mL	
				4 g/80 mL	
Zemaira (powder)	CSL Behring LLC	J0256	10 mg	1 g/20 mL	00053-7201-xx
				4 g/76 mL	00053-7202-xx
				5 g/95 mL	00053-7203-xx

## VII. References

1. Glassia [package insert]. Cambridge, MA; Takeda Pharmaceuticals USA, Inc.; February 2025. Accessed March 2026.
2. Zemaira [package insert]. Kankakee, IL; CSL Behring LLC; January 2024. Accessed March 2026.
3. Aralast NP [package insert]. Cambridge, MA; Takeda Pharmaceuticals USA, Inc.; May 2025. Accessed March 2026.
4. Prolastin-C Liquid [package insert]. Research Triangle Park, NC; Grifols Therapeutics, LLC; May 2020. Accessed March 2026.
5. Prolastin-C [package insert]. Research Triangle Park, NC; Grifols Therapeutics, LLC; January 2022. Accessed March 2024.
6. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. American Thoracic Society; European Respiratory Society. *Am J Respir Crit Care Med.* 2003 Oct 1;168(7):818-900.
7. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis (Miami).* 2016; 3(3):668-682.
8. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. *Can Respir J.* 2012;19(2):109-16.
9. Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new  $\alpha$ 1-proteinase inhibitor, Zemaira. *COPD.* 2006;3:17–23.

10. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in  $\alpha$ 1-antitrypsin deficiency. *Eur Respir J* 2017; 50.
11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Alpha1-Proteinase Inhibitor (Human). National Comprehensive Cancer Network, 2026. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2026.
12. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hematopoietic Cell Transplantation (HCT). Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2026.
13. Magenau JM, Goldstein SC, Peltier D, et al.  $\alpha$ 1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. *Blood*. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746.
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2026 Report.
15. Bornhorst JA, Greene DN, Ashwood ER, et al.  $\alpha$ 1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. *Chest*. 2013 Apr;143(4):1000-1008. doi: 10.1378/chest.12-0564. PMID: 23632999.
16. Feitosa PHR, Castellano MVCO, Costa CHD, et al. Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency. *J Bras Pneumol*. 2024 Dec 6;50(5):e20240235. doi: 10.36416/1806-3756/e20240235. PMID: 39661838; PMCID: PMC11601085.
17. Hernandez P, Bosse Y, Bush P, et al. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline. April 2025. *CHEST*, Volume 167, Issue 4, P1044-1063.

## Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
--------	------------

Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D89.810	Acute graft-versus-host disease
D89.812	Acute on chronic graft-versus-host disease
D89.813	Graft-versus-host disease, unspecified
E88.01	Alpha-1-antitrypsin deficiency
T86.09	Other complications of bone marrow transplant

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA

## Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC